Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behavior. In this review, we summarize the current progression on pRCC in molecular level. Our findings highlight the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Areas covered：This review highlights the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. Expert commentary: There are mainly two subtypes of pRCC based on histology. However, little is known about the genetic characterization of the sporadic forms of papillary renal cell carcinoma and there are currently no standard forms of therapy for patients with advanced disease. Both MET inhibitors and immunotherapy may be effective in advanced pRCC treatment. Therefore understanding the molecular basis of pRCC and identifying the main goal of treatment is crucial for the selection of the best strategy.
Expert review of anticancer therapy. 2018 Nov 24 [Epub ahead of print]
Qiwei Chen, Liang Cheng, Quanlin Li
a Department of Urology , First Affiliated Hospital of Dalian Medical University , Dalian , China., b Department of Pathology and Laboratory Medicine , Indiana University School of Medicine , Indianapolis , IN , USA .